Physician profile
Zenithe P Ware
NPI 1508061953
$5,592.16
in general payments reported to CMS, 2019-2025
31 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $641 · 2021: $700 · 2022: $877 · 2023: $1,302 · 2024: $813 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,556.81 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $954.11 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $508.59 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $306.80 | 2019-2025 | |
| Glaxosmithkline, LLC. | $273.38 | 2021-2024 | Arexvy, Shingrix, Fluarix Quadrivalent |
| Amgen INC. | $253.04 | 2019-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $223.15 | 2019-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Astrazeneca Pharmaceuticals Lp | $179.54 | 2019-2024 | Farxiga |
| Exact Sciences Corporation | $119.28 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $114.93 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $106.44 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $98.47 | 2022 | |
| Alk-Abello, INC | $97.61 | 2023-2024 | Odactra, Grastek, Ragwitek |
| Amag Pharmaceuticals, INC. | $93.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.42 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $87.10 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $80.71 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.09 | 2019 | |
| Sanofi Pasteur INC. | $53.62 | 2019-2023 | |
| Allergan, INC. | $52.08 | 2020 | |
| Cranial Technologies, INC | $41.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $39.51 | 2020 | |
| Shire North American Group INC | $33.26 | 2019 | |
| Dynavax Technologies Corporation | $31.01 | 2023 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $29.60 | 2019 | |
| Radius Health, INC. | $23.05 | 2024 | Tymlos |
| Althera Pharmaceuticals LLC | $20.81 | 2022 | |
| Ibsa Pharma INC. | $18.77 | 2025 | Licart, Flector, Tirosint |
| Phadia US INC. | $17.16 | 2023 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $15.08 | 2023 | Livalo, Seglentis |
| Idorsia Pharmaceuticals US INC | $14.84 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zenithe Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.